Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYCLOPAR vs CARISOPRODOL COMPOUND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclopar (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
Acne vulgaris,Brucellosis,Cholera,Granuloma inguinale,Listeriosis,Lymphogranuloma venereum,Mycoplasma pneumoniae infection,Psittacosis,Q fever,Rocky Mountain spotted fever,Syphilis (when penicillin contraindicated),Trachoma,Tularemia,Urinary tract infections (caused by susceptible organisms)
Relief of discomfort associated with acute, painful musculoskeletal conditions,As an adjunct to rest, physical therapy, and other measures
500 mg orally twice daily for 7-14 days.
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
4-6 hours in normal renal function; prolonged to 12-24 hours in moderate impairment; up to 48 hours in severe impairment
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Tetracycline is not extensively metabolized; primarily excreted unchanged in urine and feces.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite). Aspirin is hydrolyzed by esterases in the liver and plasma to salicylic acid, which is further conjugated. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine.
Renal (80-90% unchanged), fecal (10-20%)
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
25-30% bound to albumin
Carisoprodol is approximately 60% bound to plasma proteins, mainly albumin.
0.2-0.3 L/kg (suggests low tissue penetration; primarily extracellular fluid)
Volume of distribution is approximately 0.6–0.8 L/kg, indicating distribution into total body water.
Oral: 60-75%; IM: ~100%
Oral bioavailability is nearly complete (close to 100%) due to rapid and extensive absorption.
Cr Cl 30-50 m L/min: 500 mg once daily; Cr Cl 15-29 m L/min: 250 mg once daily; Cr Cl <15 m L/min or on dialysis: 250 mg every 48 hours.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-moderate impairment; use caution.
No adjustment required for mild to moderate impairment (Child-Pugh A or B). Severe impairment (Child-Pugh C): use with caution; consider reduced dose.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment, reduce dose or increase interval; specific guidelines not established.
For children >1 year: 15 mg/kg/day divided every 12 hours, not to exceed 500 mg per dose.
Not recommended for pediatric patients due to aspirin content and risk of Reye syndrome.
No specific dose adjustment based on age alone; dose based on renal function. Use minimum effective dose and monitor renal function.
Initiate at lowest effective dose; monitor for CNS depression, falls, and aspirin-related bleeding. Avoid in patients ≥65 years due to risks of dizziness, sedation, and GI bleeding.
Tetracycline use during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.
None
Photosensitivity: exaggerated sunburn reaction may occur.,Hepatotoxicity: rare but can occur, especially in patients with renal impairment.,Renal impairment: may require dose adjustment; avoid in severe renal dysfunction.,Pseudomembranous colitis: Clostridium difficile-associated diarrhea may occur.,Superinfection: overgrowth of nonsusceptible organisms including fungi.,Use in pregnancy: category D; avoid due to risk to fetus.,Use in children <8 years: avoid due to tooth discoloration and bone growth inhibition.
Risk of dependence, abuse, and withdrawal with carisoprodol and codeine,CYP2D6 ultrarapid metabolizers may have morphine toxicity from codeine,Reye's syndrome risk in children with viral illness (aspirin),GI bleeding risk with aspirin,Respiratory depression with codeine,Sedation and impaired motor function,Hepatic impairment,Renal impairment
Hypersensitivity to tetracycline or any component,Pregnancy (last half),Children under 8 years,Severe hepatic or renal impairment
Hypersensitivity to carisoprodol, meprobamate, aspirin, codeine, or any component,Porphyria,Acute intermittent porphyria,Children with viral illness (aspirin) due to Reye's syndrome risk,Breastfeeding (codeine),Severe renal or hepatic impairment,GI bleeding or peptic ulcer disease (aspirin),Concurrent use of MAOIs or within 14 days,Respiratory depression (codeine)
Avoid dairy products (milk, yogurt, cheese), calcium-fortified foods, and antacids containing calcium, magnesium, or aluminum within 2 hours of taking cyclopar. Iron supplements, zinc, and bismuth subsalicylate also reduce absorption. Take with a full glass of water; avoid concurrent intake of high-iron foods (e.g., spinach, red meat) within 1-2 hours. No significant interaction with alcohol but caution due to potential hepatotoxicity.
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and risk of hepatotoxicity. Grapefruit juice may inhibit metabolism, leading to increased levels and toxicity.
Cyclopar (tetracycline) is classified as FDA Pregnancy Category D. Use is contraindicated in the second and third trimesters due to risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus. Additionally, tetracyclines can cause reversible inhibition of fetal bone growth. Avoid during pregnancy; alternative antibiotics should be selected.
Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fetal harm if used during the first trimester due to possible neural tube defects based on limited reports. In the second and third trimesters, maternal use may cause neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and respiratory depression if used near term. Carisoprodol is not recommended during pregnancy unless benefit outweighs risk.
Tetracyclines are excreted into breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.5–1.5. Theoretical risks include dental staining and bone growth inhibition in the nursing infant. However, due to poor oral absorption and binding to milk calcium, systemic exposure is minimal. Use is generally considered compatible with breastfeeding if short-term; caution is advised with prolonged therapy.
Carisoprodol is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2-4 based on small studies. An infant would receive a weight-adjusted dose of about 4-8% of the maternal dose, which may cause sedation, drowsiness, or irritability in the neonate. Breastfeeding is not recommended during carisoprodol use, especially in premature infants or those with hepatic impairment. If used, monitor infant for signs of CNS depression.
No pharmacokinetic data specifically for pregnancy; standard adult dosing may be used if absolutely necessary, but use is discouraged. If unavoidable, monitor serum levels (therapeutic range 5–10 mcg/m L) as pregnancy-induced changes in volume of distribution and renal clearance may alter drug exposure. Dose adjustments should be guided by clinical response and serum levels.
No specific dosing adjustments for carisoprodol are established in pregnancy. However, due to increased plasma volume and altered hepatic metabolism in pregnancy, the drug's half-life may be reduced. Clinical monitoring for efficacy and maternal side effects (e.g., drowsiness, dizziness) is recommended. Use the lowest effective dose for the shortest duration. Consider avoidance of the compound formulation with aspirin or other NSAIDs, which have additional risks.
Cyclopar (tetracycline) should be taken on an empty stomach 1 hour before or 2 hours after meals to enhance absorption. Avoid concurrent use with dairy products, antacids, or iron supplements due to chelation. Photosensitivity is common; advise sun protection. Monitor for superinfection, especially C. difficile colitis. Use with caution in renal impairment; adjust dose to avoid nephrotoxicity. Not recommended in children under 8 years or during pregnancy due to bone and teeth discoloration.
Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential; use cautiously in patients with history of substance abuse. Combination with other CNS depressants (e.g., alcohol, benzodiazepines) increases sedation risk. Limit use to 2-3 weeks due to lack of efficacy beyond that and risk of dependence. Avoid in patients with porphyria because carisoprodol may be porphyrinogenic.
Take this medication on an empty stomach with a full glass of water, at least 1 hour before or 2 hours after meals.,Avoid dairy products, antacids, iron supplements, and calcium-rich foods for at least 2 hours before and after taking this drug.,This drug can make your skin more sensitive to sunlight; use sunscreen, wear protective clothing, and avoid tanning beds.,Complete the full course of treatment even if you feel better; do not skip doses.,Inform your doctor if you experience severe diarrhea, vaginal itching, or oral thrush as these may indicate a secondary infection.,Do not use this medication if you are pregnant, planning to become pregnant, or breastfeeding without consulting your doctor.,Store at room temperature away from moisture and heat. Do not use outdated tetracycline as it can become toxic.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or frequency. This drug has abuse potential.,Inform your doctor if you have a history of drug or alcohol abuse, seizures, or liver/kidney disease.,Do not use for longer than 2-3 weeks unless directed by your doctor.
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYCLOPAR vs CARISOPRODOL COMPOUND, answered by our medical review team.
CYCLOPAR is a Muscle Relaxant that works by Cyclopar (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.. CARISOPRODOL COMPOUND is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYCLOPAR and CARISOPRODOL COMPOUND depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYCLOPAR is: 500 mg orally twice daily for 7-14 days.. The standard adult dose of CARISOPRODOL COMPOUND is: 1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYCLOPAR and CARISOPRODOL COMPOUND in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYCLOPAR is classified as Category C. Cyclopar (tetracycline) is classified as FDA Pregnancy Category D. Use is contraindicated in the second and third trimesters due to risk of permanent tooth discoloration (yellow-gr. CARISOPRODOL COMPOUND is classified as Category A/B. Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.